Donald N. Halbert, Ph.D. Joins Iconix Pharmaceuticals as Executive Vice President of Research and Development
01 März 2005 - 2:30PM
PR Newswire (US)
Donald N. Halbert, Ph.D. Joins Iconix Pharmaceuticals as Executive
Vice President of Research and Development Former Abbott Labs
Director to Add Long-term Industry Perspective MOUNTAIN VIEW,
Calif., March 1 /PRNewswire/ -- Today, Iconix Pharmaceuticals
appointed Donald N. Halbert, Ph.D. to the role of Executive Vice
President of Research and Development. Dr. Halbert will be
responsible for all research, development and informatics
activities at Iconix. Dr. Halbert brings over two decades of proven
scientific leadership experience in large pharmaceutical R&D
and biotechnology. Prior to this appointment, Dr. Halbert had been
at Abbott Laboratories for more than 13 years. In his most recent
position he was Director of Genomics, Proteomics and Bioinformatics
in the Global Pharmaceutical Research and Development Group. In
this capacity, he was responsible for the application of human
genomics, genetics, proteomics and bioinformatics across all
therapeutic areas. The group was charged with delivering and
validating new targets, and applying leading edge technologies to
improve the process of drug discovery and development. For the past
three years, Dr. Halbert was also responsible for the
Toxicogenomics program at Abbott, and was instrumental in
establishing Abbott as a recognized industry leader in the
application of gene expression analysis to the understanding and
prediction of compound toxicity. Dr. Halbert was also the chairman
of the Abbott-Iconix scientific advisory committee, overseeing the
December 2003 alliance between the two companies. "We are very
excited about Don joining Iconix," said Jim Neal, CEO of Iconix
Pharmaceuticals. "Don was the director of a group at Abbott that is
one of the most advanced in the pharmaceutical industry in applying
chemo- and toxicogenomics to drug discovery and development. His
deep knowledge of the science of genomics combined with his
experience successfully applying that knowledge to real world drug
discovery, makes him the ideal person to lead Iconix's scientific
team." Dr. Halbert received his Ph.D. in Molecular Virology from
Washington University in St. Louis and completed a postdoctoral
fellowship with Dr. Thomas Shenk at SUNY Stony Brook. He has
published extensively and has coauthored numerous patents related
to his work. Prior to joining Abbott, Dr. Halbert held scientific
and management positions at Becton Dickinson with a focus on
molecular biology and diagnostics, and was a co-founder of the
molecular diagnostics company Gene-Trak Systems in Framingham, MA.
"I am enthusiastic about joining Iconix because I've seen the value
of the technology first-hand," said Dr. Halbert. "In my thirteen
years at Abbott, I've been responsible for numerous collaborations
with smaller companies, and in working with Iconix I found both the
science and the people to be among the best. I look forward to
sustaining the scientific focus of the company and helping to grow
the business." About Iconix: Iconix Pharmaceuticals, Inc. is
pioneering the new field of chemogenomics, the integration of
chemistry and genomics to profile drug candidates. Iconix's
chemogenomic capabilities enable pharmaceutical companies to
increase the odds of advancing the right compounds to the clinic,
reducing attrition rates and the costs of drug discovery. Iconix
provides reference systems and know-how to predict toxic
liabilities, side effects and mechanisms of drug candidates. The
company has collaborations with Bristol Myers Squibb, Abbott
Laboratories, ICOS, Eli Lilly, Schering-Plough, AstraZeneca, Taisho
Pharmaceutical Co., Ltd., Eisai Co., Ltd. and other leading
companies. Iconix also provides research, training and support to
the U.S. Food and Drug Administration, Center for Drug Evaluation
and Research (CDER) under an agreement to advance CDER's study of
the application of genomic technologies in the regulatory approval
process. Iconix's DrugMatrix system has been installed at the FDA
for use by CDER scientists and reviewers in a diverse range of
chemogenomics applications. The company also has strategic
partnerships with leading life sciences companies including MDS
Pharma Services (TSE:MDS)(NYSE:MDZ) and GE Healthcare.
Headquartered in Mountain View, California, Iconix was founded in
1998 and is privately held. For more information, visit
http://www.iconixpharm.com/. CONTACT: Jennifer Larson for Iconix
Pharmaceuticals, +1-415-409-2729, or . DATASOURCE: Iconix
Pharmaceuticals, Inc. CONTACT: Jennifer Larson for Iconix
Pharmaceuticals, +1-415-409-2729, or Web site:
http://www.iconixpharm.com/
Copyright
Mds (NYSE:MDZ)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Mds (NYSE:MDZ)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
Echtzeit-Nachrichten über Mds (New York Börse): 0 Nachrichtenartikel
Weitere Mds News-Artikel